← Back to Search

Adapted Cognitive Processing Therapy for PTSD (CPT MOST Trial)

N/A
Recruiting
Led By Rebecca Kaufman Sripada, PhD MS
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Previous receipt of CPT in the past year
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 6-week, 3-month, 6-month
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a brief, effective form of CPT against a control condition.

Who is the study for?
This trial is for Veterans over 18 with PTSD treated in PCTs, stable on psychotropic meds for at least 8 weeks, and scoring above 33 on the PCL-5. It's not for those with severe cognitive issues, psychosis or unmanaged bipolar disorder, recent CPT treatment, current detox needs, ongoing trauma-focused therapy, or acute suicide risk.
What is being tested?
The study aims to adapt Cognitive Processing Therapy (CPT) into a shorter format by identifying and delivering only its most effective components. This could reduce dropouts due to time constraints or lack of benefit and ensure that Veterans receive the best parts of CPT more efficiently.
What are the potential side effects?
While specific side effects are not listed here as it's a psychological intervention rather than a drug trial, participants may experience emotional discomfort when discussing traumatic events during therapy sessions.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have received CPT treatment within the last year.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 6-week, 3-month, 6-month
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 6-week, 3-month, 6-month for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Change
Secondary study objectives
PTSD Checklist for DSM-5 (PCL-5) Change
Patient Health Questionnaire (PHQ-9) Change

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

16Treatment groups
Active Control
Group I: 10Active Control3 Interventions
Core Session 1, Core Session 2, Modified A-B-C , Challenging Beliefs, Module Choice, Final Session
Group II: 4Active Control3 Interventions
Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Module Choice, Final Session
Group III: 11Active Control3 Interventions
Core Session 1, Core Session 2, Challenging Questions, Challenging Beliefs, Module Choice, Final Session
Group IV: 14Active Control3 Interventions
Core Session 1, Core Session 2, Modified A-B-C, Problematic Patterns, Challenging Beliefs, Final Session
Group V: 13Active Control3 Interventions
Core Session 1, Core Session 2, Problematic Patterns, Challenging Beliefs, Module Choice, Final Session
Group VI: 16Active Control5 Interventions
Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Problematic Patterns, Challenging Beliefs, Module Choice, Final Session
Group VII: 7Active Control3 Interventions
Core Session 1, Core Session 2, Challenging Questions, Problematic Patterns, Module Choice, Final Session
Group VIII: 2Active Control1 Intervention
Core Session 1, Core Session 2, Modified A-B-C, Final Session
Group IX: 3Active Control1 Intervention
Core Session 1, Core Session 2, Challenging Questions, Final Session
Group X: 5Active Control1 Intervention
Core Session 1, Core Session 2, Problematic Patterns, Final Session
Group XI: 6Active Control3 Interventions
Core Session 1, Core Session 2, Modified A-B-C, Problematic Patterns, Module Choice, Final Session
Group XII: 8Active Control3 Interventions
Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Problematic Patterns, Final Session
Group XIII: 9Active Control1 Intervention
Core Session 1, Core Session 2, Challenging Beliefs, Final Session
Group XIV: 12Active Control3 Interventions
Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Challenging Beliefs, Final Session
Group XV: 15Active Control3 Interventions
Core Session 1, Core Session 2, Challenging Questions, Problematic Patterns, Challenging Beliefs, Final Session
Group XVI: 1Active Control1 Intervention
Core Session 1, Core Session 2, Module Choice, Final Session

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,664 Previous Clinical Trials
3,765,455 Total Patients Enrolled
Rebecca Kaufman Sripada, PhD MSPrincipal InvestigatorVA Ann Arbor Healthcare System, Ann Arbor, MI
1 Previous Clinical Trials
39 Total Patients Enrolled

Media Library

Cognitive Processing Therapy Clinical Trial Eligibility Overview. Trial Name: NCT05220137 — N/A
Post-Traumatic Stress Disorder Research Study Groups: 10, 4, 11, 14, 13, 16, 7, 2, 3, 5, 6, 8, 9, 12, 15, 1
Post-Traumatic Stress Disorder Clinical Trial 2023: Cognitive Processing Therapy Highlights & Side Effects. Trial Name: NCT05220137 — N/A
Cognitive Processing Therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05220137 — N/A
~62 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top